Comparative Pharmacology
Head-to-head clinical analysis: RITALIN LA versus RITALIN SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RITALIN LA versus RITALIN SR.
RITALIN LA vs RITALIN-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
20-60 mg orally once daily in the morning; capsules may be swallowed whole or sprinkled on applesauce.
20 mg orally twice daily, typically 30-45 minutes before breakfast and lunch; maximum 60 mg/day.
None Documented
None Documented
Methylphenidate: 3–4 hours (racemic); d-enantiomer: 6–8 hours; clinical context: duration of action 8–12 hours due to extended-release formulation
2-3 hours for the immediate-release component; sustained-release formulation shows biphasic elimination with terminal half-life of 2-4 hours.
Renal (78–97% as metabolites, primarily ritalinic acid, with <1% unchanged); fecal <2%
Primarily renal (90%) as metabolites including ritalinic acid, with 1-3% unchanged; minor biliary/fecal elimination.
Category C
Category C
Central Nervous System Stimulant
Central Nervous System Stimulant